Skip to main content

Table 1 Clinical characteristics of ESA and HIF stabilizer

From: A new insight into the treatment of renal anemia with HIF stabilizer

Drug EPO origin EPO concentration at peak Route Correction of anemia Adverse events
ESA Exogenous High (overshooting) IV or SC Correction of anemia Hypertension thrombosis
HIF-S Endogenous Within physiological levels Oral Effective (especially, nondialysis) Thrombosis/embolism pulmonary hypertension/ADPKD/malignancy/retinopathy/hyperkalemia hypertension?
  1. ESA erythropoiesis stimulating agent, HIF-S HIF stabilizer, ADPKD autosomal dominant polycystic kidney disease, IV intravenous use, SC subcutaneous use
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us

\